Olema Pharmaceuticals Statistics
Total Valuation
OLMA has a market cap or net worth of $474.09 million. The enterprise value is $261.03 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OLMA has 57.26 million shares outstanding. The number of shares has increased by 29.11% in one year.
| Current Share Class | 57.26M |
| Shares Outstanding | 57.26M |
| Shares Change (YoY) | +29.11% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 5.12% |
| Owned by Institutions (%) | 58.44% |
| Float | 28.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.38 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.10, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.10 |
| Quick Ratio | 7.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.76% and return on invested capital (ROIC) is -36.24%.
| Return on Equity (ROE) | -51.76% |
| Return on Assets (ROA) | -33.15% |
| Return on Capital (ROIC) | -36.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 74 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.96% in the last 52 weeks. The beta is 2.03, so OLMA's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -47.96% |
| 50-Day Moving Average | 11.77 |
| 200-Day Moving Average | 12.02 |
| Relative Strength Index (RSI) | 22.88 |
| Average Volume (20 Days) | 440,567 |
Short Selling Information
The latest short interest is 8.31 million, so 14.51% of the outstanding shares have been sold short.
| Short Interest | 8.31M |
| Short Previous Month | 8.50M |
| Short % of Shares Out | 14.51% |
| Short % of Float | 28.86% |
| Short Ratio (days to cover) | 24.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -138.71M |
| Pretax Income | -109.63M |
| Net Income | -122.68M |
| EBITDA | -138.34M |
| EBIT | -138.71M |
| Earnings Per Share (EPS) | -$2.29 |
Full Income StatementBalance Sheet
The company has $214.76 million in cash and $1.70 million in debt, giving a net cash position of $213.06 million or $3.72 per share.
| Cash & Cash Equivalents | 214.76M |
| Total Debt | 1.70M |
| Net Cash | 213.06M |
| Net Cash Per Share | $3.72 |
| Equity (Book Value) | 198.91M |
| Book Value Per Share | 3.47 |
| Working Capital | 187.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$96.54 million and capital expenditures -$159,000, giving a free cash flow of -$96.70 million.
| Operating Cash Flow | -96.54M |
| Capital Expenditures | -159,000 |
| Free Cash Flow | -96.70M |
| FCF Per Share | -$1.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |